Italy Epigenetics Market Size & Outlook, 2023-2030

The epigenetics market in Italy is expected to reach a projected revenue of US$ 1,266.4 million by 2030. A compound annual growth rate of 13.3% is expected of Italy epigenetics market from 2024 to 2030.
Revenue, 2023 (US$M)
$527.7
Forecast, 2030 (US$M)
$1,266.4
CAGR, 2024 - 2030
13.3%
Report Coverage
Italy

Italy epigenetics market highlights

  • The Italy epigenetics market generated a revenue of USD 527.7 million in 2023 and is expected to reach USD 1,266.4 million by 2030.
  • The Italy market is expected to grow at a CAGR of 13.3% from 2024 to 2030.
  • In terms of segment, reagents was the largest revenue generating product in 2023.
  • Services is the most lucrative product segment registering the fastest growth during the forecast period.


Epigenetics market data book summary

Market revenue in 2023USD 527.7 million
Market revenue in 2030USD 1,266.4 million
Growth rate13.3% (CAGR from 2023 to 2030)
Largest segmentReagents
Fastest growing segmentServices
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationReagents, Kits, Instruments, Enzymes, Services
Key market players worldwideRoche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC


Other key industry trends

  • In terms of revenue, Italy accounted for 3.6% of the global epigenetics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany epigenetics market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 3,381.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Epigenetics Market Companies

Name Profile # Employees HQ Website

Italy epigenetics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.


Reagents was the largest segment with a revenue share of 34.58% in 2023. Horizon Databook has segmented the Italy epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.


The Italy epigenetics Market is growing and is driven by strategic funding initiatives. According to an article by the LA biotech UG, Sofinnova's Partners invested €6 million (USD 6,588 million) in Italian gene therapy companies, further solidifying Italy's status as a key hub for cell and gene therapies in Europe.

The financial backing, directed through Sofinnova's Telethon Fund, supported AA Vantgarde Bio, Alia Therapeutics, and Borea Therapeutics, providing seed capital (USD 6,588 million) for the development of treatments targeting rare genetic diseases.

Established in collaboration with the Telethon Foundation charity, Sofinnova's Telethon Fund has stood as Italy's largest investment pot for biotechnology since 2018. Over three decades, the Telethon Foundation has been instrumental in supporting research for new treatments for rare & genetic disorders, contributing to the thriving landscape of gene therapy startups and academic excellence in Italy.

Reasons to subscribe to Italy epigenetics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Italy epigenetics market databook

  • Our clientele includes a mix of epigenetics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Italy epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into Italy epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Italy epigenetics market size, by product, 2018-2030 (US$M)

Italy Epigenetics Market Outlook Share, 2023 & 2030 (US$M)

Italy epigenetics market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more